MAP BioPharma
Case Study

MAP’s vision to accelerate patient access to medicines, devices and diagnostics is at the heart of everything we do.

Case study 3:

Supporting our client through the UK Promising Innovative Medicine (PIM) designation as part of the Early Access to Medicines Scheme (EAMS)


  •  Our client was keen to explore ways in which patient access to their product could be accelerated in the UK.

  •  They had heard of PIM and EAMS but were not sure if their product would qualify and whether the process would be a worthwhile investment of their time.

  •  MAP was engaged to help understand whether this would be the right approach and to provide ongoing support if the client decided to proceed.


  •  Confidential conversations with key stakeholders at MHRA, NICE and NHS England helped to assess feasibility and build support for our client’s PIM submission.

  •  In parallel, we helped to pressure test the clients’ value proposition and work with them to ensure it was optimised for a PIM submission.

  •  We provided support in preparing the PIM submission as well as engaging clinical experts to inform the response.


  • MAP managed to secure PIM designation for our client and support them to achieve full EAMS scientific opinion.

  •  Our client’s product was brought to market in the UK eight months faster than would have been the case without pursuing PIM and EAMS.

Case study-diagram
CareersTerms and ConditionsComplaints ProcedurePrivacy PolicyCookie Policy

Copyright © 2021.
MAP BioPharma Limited.
All rights reserved.

MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom

 +44 (0) 1480 832360

MAP BioPharma Limited is a registered company in England and Wales.
Company Registration Number 08209281

VAT Group Registration Number:
GB 292 8576 52